Aurenar Closes Oversubscribed $5.7M Seed Round Led by the Go Red for Women Venture Fund™ and Solas BioVentures

Aurenar has successfully closed a $5.7 million seed financing round, co-led by the Go Red for Women Venture Fund and Solas BioVentures. The funding, announced on July 28, 2026, will be utilized to advance Aurenar's innovative non-invasive neuromodulation platform, V-Link™, which aims to improve stroke care in intensive care units (ICUs). The investment will specifically support pivotal trials, final device development, verification and validation testing, and regulatory submissions to the U.S. Food and Drug Administration (FDA).

Aurenar's V-Link™ platform has recently received breakthrough device designation from the FDA, highlighting its potential to significantly impact stroke treatment and broader neurocritical care challenges. The device employs transauricular vagus nerve stimulation (taVNS) to modulate the body's inflammatory response, which is critical in addressing complications associated with conditions such as subarachnoid hemorrhage (SAH). This condition accounts for approximately 7% of all strokes globally, with nearly 40% of survivors facing permanent disabilities. By targeting inflammation, Aurenar's technology addresses a significant unmet need in critical care, offering the possibility of better recovery trajectories for patients facing acute, high-risk situations.

The strategic rationale behind this funding round is underscored by the growing recognition of the importance of addressing inflammatory responses in critically ill patients. Aurenar's platform not only shows promise in stroke care but also has the potential to expand into other high-impact indications within the ICU setting. The simplicity and wireless design of the V-Link device facilitate ease of use for healthcare professionals, which is critical for rapid clinical adoption and effective patient management.

The investment from the Go Red for Women Venture Fund is particularly noteworthy, as it aligns with the fund's mission to support innovations that improve health outcomes for women, who are disproportionately affected by stroke and related complications. This partnership not only provides financial backing but also enhances Aurenar's credibility in the healthcare innovation space, positioning the company for future growth and development.

The successful close of this funding round signals a positive outlook for Aurenar and the broader neuromodulation sector. As healthcare continues to evolve with a focus on patient-centered solutions, the advancements made by Aurenar may pave the way for transformative changes in stroke care and critical illness management. This development reflects a growing trend in the medical technology landscape, where innovative solutions are increasingly recognized as essential for improving patient outcomes and reducing healthcare costs.